Myocarditis after BNT162b2 vaccination in a healthy male

Watkins, Kevin; Griffin, Gregory; Septaric, Kristen; Simon, Erin L.

doi:10.1016/j.ajem.2021.06.051

Cited by 45 publications

(30 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A final selection of 56 studies was selected for adverse cardiac events after vaccination, with a total of 340 patients. Eleven studies described cardiac AEs following influenza vaccination [ 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 ], and 18 studies described cardiac AEs after COVID-19 vaccination [ 6 , 7 , 8 , 9 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 ]. There were 20 studies reporting cardiac AEs after smallpox vaccination [ 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 ].…”

Section: Resultsmentioning

confidence: 99%

Cardiac Adverse Events after Vaccination—A Systematic Review

et al. 2022

View full text Add to dashboard Cite

The Vaccine Adverse Event Reporting System database has been used to report adverse events following several vaccines. We studied the patient population predisposed to such reactions and how these reactions differ with respect to the vaccine type. We searched the electronic databases PubMed, EMBASE, and Scopus up to 9 July 2021 for any study describing cardiac adverse events attributed to the vaccination. A total of 56 studies met the criteria comprising 340 patients. There were 20 studies describing cardiac adverse events following smallpox vaccination, 11 studies describing adverse events after influenza vaccination, and 18 studies describing adverse events after COVID-19 vaccination. There was a total of six studies describing cardiac adverse events after the pneumococcal vaccine, tetanus toxoid, cholera vaccine, and rabies vaccine. Adverse events following influenza vaccination occurred more commonly in older females within an average duration of four days from vaccination. Pericardial involvement was the most reported adverse event. Adverse events following COVID-19 vaccination happened at a mean age of 42.7 years, more commonly in males, and mostly after a second dose. Adverse events following smallpox vaccination occurred more commonly in younger males, with an average onset of symptoms from vaccination around 16.6 days. Adverse events were mostly myopericarditis; however, the acute coronary syndrome has been reported with some vaccines.

show abstract

Section: Resultsmentioning

confidence: 99%

Cardiac Adverse Events after Vaccination—A Systematic Review

et al. 2022

View full text Add to dashboard Cite

show abstract

“…After reviewing individual abstracts and full texts of the articles, we identified 20 studies (12 case reports and 8 case series) that met the inclusion criteria for this systematic review. 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 In addition, we carried out an additional search in the same databases on September 10, 2021, and added one case series and three case reports. 30 , 31 , 32 , 33 The search terms used are described in detail in Table S2 .…”

Section: Methodsmentioning

confidence: 99%

Clinical characteristics and prognostic factors of myocarditis associated with the mRNA COVID‐19 vaccine

Woo

Kim

Yon

et al. 2021

Journal of Medical Virology

View full text Add to dashboard Cite

To analyze the clinical presentation and outcomes of myocarditis after administration of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccine. Nine case series and 15 case reports (74 patients) of myocarditis after administration of the BNT162b2 or mRNA-1273 vaccine were reviewed from PubMed, Scopus, Embase, and Web of Science. We analyzed clinical manifestations, diagnostic findings, and outcomes. In addition, we performed a pooled analysis and investigated risk factors leading to admission to the intensive care unit and recovery with conservative care. Most patients were male (94.6%), and the median age (range) was 17.6 (14-70) years. Patients who received the BNT162b2 (n = 58, 78.4%) vaccine presented fewer systemic symptoms and left ventricular dysfunction than mRNA-1273 recipients. Although patients under 20 years experienced more fever and myalgia, they had better ejection fraction and less prominent myocardial inflammation in magnetic resonance imaging than older patients. The clinical course of all patients was favorable without mortality, and onethird of patients resolved with conservative care alone. Risk factor analyses revealed that patients with gastrointestinal symptoms required intensive care

show abstract

“… 10 Myocarditis cases have been reported following mRNA COVID‐19 vaccination and early analyses suggested it may constitute a complication of these vaccines. 11 , 12 , 13 …”

mentioning

confidence: 99%

Features of Inflammatory Heart Reactions Following mRNA COVID‐19 Vaccination at a Global Level

Chouchana

Blet

Al-Khalaf

et al. 2021

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

Myocarditis and pericarditis may constitute adverse reactions of mRNA coronavirus disease 2019 (COVID‐19) vaccines. This study aimed to document these reactions and to assess the association with patient sex and age. This is as an observational retrospective study using a case–non‐case design (also called disproportionality study) on inflammatory heart reactions reported with mRNA COVID‐19 vaccines within the World Health Organization (WHO) global safety database (VigiBase), up to June 30, 2021. Results are expressed using reporting odds ratios (RORs) and their 95% confidence interval (95% CI). Of 716,576 reports related to mRNA COVID‐19 vaccines, 2,277 were cases of inflammatory heart reactions, including 1241 (55%) myocarditis and 851 (37%) pericarditis. The main age group was 18–29 years (704, 31%), and mostly male patients (1,555, 68%). Pericarditis onset was delayed compared with myocarditis with a median time to onset of 8 (3–21) vs. 3 (2–6) days, respectively (P = 0.001). Regarding myocarditis, an important disproportionate reporting was observed in adolescents (ROR, 22.3, 95% CI 19.2–25.9) and in 18–29 years old (ROR, 6.6, 95% CI 5.9–7.5) compared with older patients, as well as in male patients (ROR, 9.4, 95% CI 8.3–10.6). Reporting rate of myocarditis was increased in young adults and adolescents. Inflammatory heart reactions may rarely occur shortly following mRNA COVID‐19 vaccination. Although an important disproportionate reporting of myocarditis was observed among adolescents and young adults, particularly in male patients, reporting rates support a very rare risk, that does not seem to compromise the largely positive benefit‐risk balance of these vaccines. Furthermore, this study confirmed the value of disproportionality analyses for estimation of relative risks among subgroups of patients.

show abstract

Myocarditis after BNT162b2 vaccination in a healthy male

Cited by 45 publications

References 6 publications

Cardiac Adverse Events after Vaccination—A Systematic Review

Cardiac Adverse Events after Vaccination—A Systematic Review

Clinical characteristics and prognostic factors of myocarditis associated with the mRNA COVID‐19 vaccine

Features of Inflammatory Heart Reactions Following mRNA COVID‐19 Vaccination at a Global Level

Contact Info

Product

Resources

About